Cancer Biotherapy and Radiopharmaceuticals
Editor-in-Chief: Martin W. Brechbiel, PhD
Latest Impact Factor* is 1.682
*2017 Journal Citation Reports® (Clarivate Analytics, 2018)
The definitive source for peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer .View Aims & Scope…
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.